(secondQuint)Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).

.

 Eligible patients will be randomized to one of the following two treatment arms: 1.

 Budesonide MMX 9 mg (one tablet) 2.

 Placebo (tablet indistinguishable from budesonide MMX 9 mg tablet) The assigned study drug will be taken as a single oral tablet each morning after breakfast.

 In addition to the study drug, all patients will continue their existing background oral 5-ASA regimen during the treatment period.

.

 Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).

@highlight

This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in patients with active, mild or moderate ulcerative colitis (UC).

